CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88L265P-directed survival signalling in Waldenström macroglobulinaemia cells

British Journal of Haematology

Volumn 168, Issue 5, 2015, Pages 701-707

  Cao, Yang ^a,b   Hunter, Zachary R ^a,c   Liu, Xia ^a,b   Xu, Lian ^a   Yang, Guang ^a,b   Chen, Jie ^a   Tsakmaklis, Nickolas ^a   Kanan, Sandra ^a   Castillo, Jorge J ^a,b   Treon, Steven P ^a,b  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

WHIM; CXCR4; Ibrutinib; MYD88; Waldenstr m macroglobulinaemia

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; IBRUTINIB; MITOGEN ACTIVATED PROTEIN KINASE 1; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN KINASE B; PROTEIN KINASE B1; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG; CXCL12 PROTEIN, HUMAN; CXCR4 PROTEIN, HUMAN; MYD88 PROTEIN, HUMAN; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; STOP CODON; TUMOR PROTEIN;

APOPTOSIS; ARTICLE; CELL STIMULATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG SENSITIVITY; ENZYME ACTIVATION; FRAMESHIFT MUTATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; INTERNALIZATION; INTRACELLULAR SIGNALING; NONSENSE MUTATION; PROTEIN EXPRESSION; SOMATIC MUTATION; WALDENSTROEM MACROGLOBULINEMIA; WARTS HYPOGAMMAGLOBULINAEMIA INFECTIONS AND MYELOKATHEXIS SYNDROME; WILD TYPE; AMINO ACID SUBSTITUTION; DRUG EFFECTS; DRUG RESISTANCE; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; STOP CODON; TUMOR CELL CULTURE;

AMINO ACID SUBSTITUTION; APOPTOSIS; CELL SURVIVAL; CHEMOKINE CXCL12; CODON, NONSENSE; DRUG RESISTANCE, NEOPLASM; FRAMESHIFT MUTATION; HUMANS; MYELOID DIFFERENTIATION FACTOR 88; NEOPLASM PROTEINS; PYRAZOLES; PYRIMIDINES; RECEPTORS, CXCR4; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; WALDENSTROM MACROGLOBULINEMIA;

EID: 84922832325     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13200     Document Type: Article

References (20)

1. Ansell, S.M., Hodge, L.S., Secreto, F.J., Manske, M., Braggio, E., Price-Troska, T., Ziesmer, S., Li, Y., Johnson, S.H., Hart, S.N., Kocher, J.P., Vasmatzis, G., Chanan-Kahn, A., Gertz, M., Fonseca, R., Dogan, A., Cerhan, J.R. & Novak, A.J. (2014) Activation of TAK1 by MYD88 L265P drives malignant B-cell growth in non-Hodgkin lymphoma. Blood Cancer Journal, 14, e183.
2. Busillo, J.M. & Benovic, J.L. (2007) Regulation of CXCR4 signaling. Biochimica Biophysica Acta, 1768, 952-963.
3. Busillo, J.M., Armando, S., Sengupta, R., Meucci, O., Bouvier, M. & Benovic, J.L. (2010) Site-specific phosphorylation of CXCR4 is dynamically regulated by multiple kinases and results in differential modulation of CXCR4 signaling. Journal of Biological Chemistry, 285, 7805-7817.
4. S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia. Leukemia, doi: 10.1038/leu.2014.187.
5. Dotta, L., Tassone, L. & Badolato, R. (2011) Clinical and genetic features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) syndrome. Current Molecular Medicine, 11, 317-325.
6. Futahashi, Y., Koman, J., Urano, E., Aoki, T., Hamatake, M., Miyauchi, K., Yoshida, T., Matsuda, Z. & Yamamoto, N. (2007) Separate elements are required for ligand-dependent and independent internalization of metastatic potentiator CXCR4. Cancer Science, 98, 373-379.
7. Hunter, Z.R., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Manning, R.J., Tripsas, C., Patterson, C.J., Sheehy, P. & Treon, S.P. (2014) The genomic landscape of Waldenstöm's Macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis. Blood, 123, 1637-1646.
8. Jimenez, C., Sebastian, E., Chillon, M.C., Giraldo, P., Mariano Hernandez, J., Escalante, F., Gonzalez-Lopez, T.J., Aguilera, C., de Coca, A.G., Murillo, I., Alcoceba, M., Balanztegui, A., Sarasquete, M.E., Corral, R., Marin, L.A., Paiva, B., Ocio, E.M., Gutierrez, N.C., Gonzalez, M., San Miguel, J.F. & Garcia-Sanz, R. (2013) MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenstrom's macroglobulinemia. Leukemia, 27, 1722-1728.
9. Lagane, B., Chow, K.Y.C., Balabanian, K., Levoye, A., Harriague, J., Planchenault, T., Baleux, F., Gunera-Saad, N., Arenzana-Seisdedos, F. & Bachelerie, F. (2008) CXCR4 dimerization and β-arrestin mediated signaling account for the enhanced chemotaxis to CXCL12 in WHIM syndrome. Blood, 112, 34-44.
10. Leleu, X., Jia, X., Runnels, J., Ngo, H.T., Moreau, A.S., Farag, M., Spencer, J.A., Pitsillides, C.M., Hatjiharissi, E., Roccaro, A., O'Sullivan, G., McMillin, D.W., Moreno, D., Kiziltepe, T., Carrasco, R., Treon, S.P., Hideshima, T., Anderson, K.C., Lin, C.P. & Ghobrial, I.M. (2007) The Akt pathway regulates survival and homing in Waldenstrom macroglobulinemia. Blood, 110, 4417-4426.
11. Leleu, X., Eeckhoute, J., Jia, X., Roccaro, A.M., Moreau, A.S., Farag, M., Sacco, A., Ngo, H.T., Runnels, J., Melhem, M.R., Burwick, N., Azab, A., Azab, F., Hunter, Z., Hatjiharissi, E., Carrasco, D.R., Treon, S.P., Witzig, T.E., Hideshima, T., Brown, M., Anderson, K.C. & Ghobrial, I.M. (2008) Targeting NF-kappaB in Waldenstrom macroglobulinemia. Blood, 111, 5068-5077.
12. McDermott, D.H., Liu, Q., Velez, D., Lopez, L., Anaya-O'Brien, S., Ulrick, J., Kwatemaa, N., Starling, J., Fleisher, T.A., Priel, D.A., Merideth, M.A., Giuntoli, R.L., Evbuomwan, M.O., Littel, P., Marquesen, M.M., Hilligoss, D., DeCastro, R., Grimes, G.J., Hwang, S.T., Pittaluga, S., Calvo, K.R., Stratton, P., Cowen, E.W., Kuhns, D.B., Malech, H.L. & Murphy, P.M. (2014) A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor. Blood, 123, 2308-2316.
13. Mueller, W., Schütz, D., Nagel, F., Schulz, S. & Stumm, R. (2013) Hierarchical organization of multisite phosphorylation at the CXCR4 C terminus. PLoS One, 8, e64975.
14. Poulain, S., Roumier, C., Decambron, A., Renneville, A., Herbaux, C., Bertrand, E., Tricot, S., Daudignon, A., Galiègue-Zouitina, S., Soenen, V., Theisen, O., Grardel, N., Nibourel, O., Roche-Lestienne, C., Quesnel, B., Duthilleul, P., Preudhomme, C. & Leleu, X. (2013) MYD88 L265P mutation in Waldenstrom macroglobulinemia. Blood, 121, 4504-4511.
15. Roccaro, A.M., Sacco, A., Jimenez, C., Maiso, P., Moschetta, M., Mishima, Y., Aljawai, Y., Sahin, I., Kuhne, M., Cardarelli, P., Cohen, L., San Miguel, J.F., Garcia-Sanz, R. & Ghobrial, I.M. (2014) C1013G/CXCR4 acts as a driver mutation of tumor progression and modulator of drug resistance in lymphoplasmacytic lymphoma. Blood, 123, 4120-4131.
16. Treon, S.P., Xu, L., Yang, G., Zhou, Y., Liu, X., Cao, Y., Sheehy, P., Manning, R.J., Patterson, C.J., Tripsas, C., Arcaini, L., Pinkus, G.S., Rodig, S.J., Sohani, A.R., Harris, N.L., Laramie, J.M., Skifter, D.A., Lincoln, S.E. & Hunter, Z.R.M. (2012) YD88 L265P somatic mutation in Waldenstrom's macroglobulinemia. New England Journal of Medicine, 367, 826-833.
17. Treon, S.P., Tripsas, C., Yang, G., Cao, Y., Xu, L., Hunter, Z.R., Cropper, S.J., Mostyn, P., Meid, K., Warren, D., Patterson, C.J., Varma, G., Laubach, J.P., Paba-Prada, C.E., Kunsman, J., Ghobrial, I.M., Kanan, S., Advani, R.H. & Palomba, M.L. (2013) A prospective multicenter study of the Bruton's tyrosine kinase inhibitor ibrutinib in patients with relapsed or refractory Waldenstrom's macroglobulinemia. Blood, 122, Abstract 251.
18. Treon, S.P., Cao, Y., Xu, L., Yang, G., Liu, X. & Hunter, Z.R. (2014) Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom's macroglobulinemia. Blood, 123, 2791-2796.
19. Varettoni, M., Arcaini, L., Zibellini, S., Boveri, E., Rattotti, S., Riboni, R., Corso, A., Orlandi, E., Bonfichi, M., Gotti, M., Pascutto, C., Mangiacavalli, S., Croci, G., Fiaccadori, V., Morello, L., Guerrera, M.L., Paulli, M. & Cazzola, M. (2013) Prevalence and clinical significance of the MYD88 L265P somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms. Blood, 121, 2522-2528.
20. Yang, G., Zhou, Y., Liu, X., Xu, L., Cao, Y., Manning, R.J., Patterson, C.J., Buhrlage, S.J., Gray, N., Tai, Y.T., Anderson, K.C., Hunter, Z.R. & Treon, S.P. (2013) A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenstrom macroglobulinemia. Blood, 122, 1222-1232.